文献速递糖尿病

GLIS3致病性单等位基因变异增加2型糖尿病风险并识别对磺脲类药物敏感的患者亚组

Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas.
PubMed 文献 · Diabetologia · 2023-12-05

在RaDiO研究中测序5471人的GLIS3,按ACMG标准鉴定致病/可能致病变异,用荧光素酶试验评估对INS启动子的激活能力。合并RaDiO、52K和TOPMed的Meta分析显示,P/LP GLIS3变异在2型糖尿病患者中富集(p=5.6×10-5;OR 2.1 [95% CI 1.4, 2.9]),且所有携带变异的2型糖尿病患者均对口服磺脲类药物敏感。

要点

  • 罕见P/LP GLIS3变异与2型糖尿病风险升高相关,Meta分析OR 2.1(95% CI 1.4, 2.9)。
  • RaDiO中P/LP变异负荷在2型糖尿病患者中更高(p=3.0×10-3;OR 3.9 [95% CI 1.4, 12])。
  • 所有携带P/LP变异且患2型糖尿病的患者均对口服磺脲类药物敏感。

核心结论

  • 罕见P/LP GLIS3变异确实增加2型糖尿病风险。
  • 位于蛋白远端部分的变异可能通过影响反式激活结构域直接改变其功能活性。
  • 罕见P/LP GLIS3变异似乎对β细胞功能有直接临床影响,可通过使用磺脲类药物增加胰岛素分泌而改善。

研究设计与样本

  • 在罕见变异与糖尿病和肥胖(RaDiO)研究的5471人中测序GLIS3。
  • 按美国医学遗传学与基因组学学会(ACMG)标准评估变异致病性。
  • 用荧光素酶试验检测GLIS3结合并激活INS启动子的能力以评估PS3标准。
  • 将RaDiO、52K研究(43,125人)和TOPMed研究(44,083人)的关联结果进行Meta分析。

主要发现

  • 靶向重测序鉴定出105个罕见变异,由RaDiO的395名参与者携带。
  • 49个变异降低INS启动子激活。
  • 18个罕见变异按ACMG标准分类为P/LP,与其余外显子相比富集于最后两个外显子(p<5×10-6;OR>3.5)。
  • P/LP变异负荷在2型糖尿病患者中更高(p=3.0×10-3;OR 3.9 [95% CI 1.4, 12])。
  • 在52K和TOPMed研究中均鉴定出7个P/LP变异;Meta分析显示P/LP GLIS3变异在2型糖尿病患者中富集(p=5.6×10-5;OR 2.1 [95% CI 1.4, 2.9])。

关键数值与推荐

  • P/LP变异负荷在2型糖尿病患者中更高:p=3.0×10-3;OR 3.9(95% CI 1.4, 12)。
  • P/LP变异富集于最后两个外显子:p<5×10-6;OR>3.5。
  • Meta分析:P/LP GLIS3变异在2型糖尿病患者中富集,p=5.6×10-5;OR 2.1(95% CI 1.4, 2.9)。

临床怎么用

  • 所有携带P/LP变异且患2型糖尿病的患者均对口服磺脲类药物敏感。
  • 作者认为罕见P/LP GLIS3变异似乎对β细胞功能有直接临床影响,可通过使用磺脲类药物增加胰岛素分泌而改善。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: GLIS3 encodes a transcription factor involved in pancreatic beta cell development and function. Rare pathogenic, bi-allelic mutations in GLIS3 cause syndromic neonatal diabetes whereas frequent SNPs at this locus associate with common type 2 diabetes risk. Because rare, functional variants located in other susceptibility genes for type 2 diabetes have already been shown to strongly increase individual risk for common type 2 diabetes, we aimed to investigate the contribution of rare pathogenic GLIS3 variants to type 2 diabetes. METHODS: GLIS3 was sequenced in 5471 individuals from the Rare Variants Involved in Diabetes and Obesity (RaDiO) study. Variant pathogenicity was assessed following the criteria established by the American College of Medical Genetics and Genomics (ACMG). To address the pathogenic strong criterion number 3 (PS3), we conducted functional investigations of these variants using luciferase assays, focusing on capacity of GLIS family zinc finger 3 (GLIS3) to bind to and activate the INS promoter. The association between rare pathogenic or likely pathogenic (P/LP) variants and type 2 diabetes risk (and other metabolic traits) was then evaluated. A meta-analysis combining association results from RaDiO, the 52K study (43,125 individuals) and the TOPMed study (44,083 individuals) was finally performed. RESULTS: Through targeted resequencing of GLIS3, we identified 105 rare variants that were carried by 395 participants from RaDiO. Among them, 49 variants decreased the activation of the INS promoter. Following ACMG criteria, 18 rare variants were classified as P/LP, showing an enrichment in the last two exons compared with the remaining exons (p<5×10-6; OR>3.5). The burden of these P/LP variants was strongly higher in individuals with type 2 diabetes (p=3.0×10-3; OR 3.9 [95% CI 1.4, 12]), whereas adiposity, age at type 2 diabetes diagnosis and cholesterol levels were similar between variant carriers and non-carriers with type 2 diabetes. Interestingly, all carriers with type 2 diabetes were sensitive to oral sulfonylureas. A total of 7 P/LP variants were identified in both 52K and TOPMed studies. The meta-analysis of association studies obtained from RaDiO, 52K and TOPMed showed an enrichment of P/LP GLIS3 variants in individuals with type 2 diabetes (p=5.6×10-5; OR 2.1 [95% CI 1.4, 2.9]). CONCLUSIONS/INTERPRETATION: Rare P/LP GLIS3 variants do contribute to type 2 diabetes risk. The variants located in the distal part of the protein could have a direct effect on its functional activity by impacting its transactivation domain, by homology with the mouse GLIS3 protein. Furthermore, rare P/LP GLIS3 variants seem to have a direct clinical effect on beta cell function, which could be improved by increasing insulin secretion via the use of sulfonylureas.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Meulebrouck S, Scherrer V, Boutry R, et al. Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas. Diabetologia. 2023. PMID: 38051360. doi:10.1007/s00125-023-06035-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。